- Home
- CNX vs JAZZ Comparison
CNX vs JAZZ Comparison
Compare CNX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | JAZZ |
|---|---|---|
| Founded | 1860 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 10.8B |
| IPO Year | 1999 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CNX | JAZZ |
|---|---|---|
| Price | $36.51 | $170.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $34.50 | ★ $199.20 |
| AVG Volume (30 Days) | ★ 2.1M | 969.1K |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | $1,930,542,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $49.64 | $6.00 |
| Revenue Next Year | $2.18 | $6.47 |
| P/E Ratio | $18.15 | ★ N/A |
| Revenue Growth | ★ 40.99 | 4.14 |
| 52 Week Low | $27.00 | $95.49 |
| 52 Week High | $42.13 | $182.99 |
Technical Indicators
Market Signals| Indicator | CNX | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 60.06 |
| Support Level | $36.84 | $164.39 |
| Resistance Level | $37.99 | $172.69 |
| Average True Range (ATR) | 1.18 | 4.02 |
| MACD | -0.49 | -0.72 |
| Stochastic Oscillator | 1.75 | 83.49 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.